AQEMIA Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
85
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$7.4M
- Investors
-
14
AQEMIA General Information
Description
Developer of a drug discovery platform designed to discover new drugs for specific therapeutic targets. The company's platform combines machine learning and quantum-inspired statistical mechanics algorithms to generate lead-like molecules for a given target, enabling researchers to efficiently and accurately predict the affinity between drug candidates and therapeutic targets.
Contact Information
Website
www.aqemia.comCorporate Office
- 1 Boulevard Pasteur
- 75015 Paris
- France
Corporate Office
- 1 Boulevard Pasteur
- 75015 Paris
- France
AQEMIA Timeline
AQEMIA Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Grant | 01-Apr-2025 | $7.4M | Completed | Generating Revenue | ||
| 12. Later Stage VC (Series A3) | 10-Dec-2024 | Completed | Generating Revenue | |||
| 11. Accelerator/Incubator | 14-Jun-2023 | Completed | Generating Revenue | |||
| 10. Accelerator/Incubator | 01-Jan-2023 | Completed | Generating Revenue | |||
| 9. Early Stage VC (Series A2) | 19-Oct-2022 | Completed | Generating Revenue | |||
| 8. Early Stage VC (Series A1) | 02-May-2021 | Completed | Generating Revenue | |||
| 7. Early Stage VC | 10-Dec-2020 | Completed | Generating Revenue | |||
| 6. Seed Round | 17-Oct-2019 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 01-Jun-2019 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 01-Jan-2019 | Completed | Generating Revenue |
AQEMIA Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| A2 Shares | ||||||||
| A Shares | ||||||||
| Ordinary | 27,400 | $0.010545 | $2.69 | $2.69 | 1x | $2.69 | 1.09% | |
| A Shares | 333,500 | $0.010545 | $3.16 | $3.16 | 1x | $3.16 | 13.22% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
AQEMIA Comparisons
Industry
Financing
Details
AQEMIA Competitors (9)
One of AQEMIA’s 9 competitors is insitro, a Venture Capital-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| insitro | Venture Capital-Backed | South San Francisco, CA | ||||
| Exscientia | Formerly VC-backed | Oxford, United Kingdom | ||||
| AbCellera Biologics | Formerly VC-backed | Vancouver, Canada | ||||
| Ariana Pharma | Formerly VC-backed | Paris, France | ||||
| Relay Therapeutics | Formerly VC-backed | Cambridge, MA |
AQEMIA Patents
AQEMIA Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025252767-A1 | 3-(1h-indazol-3-yl)isoquinoline derivatives as map4k1 (hpk1) inhibitors and use thereof in therapy | Pending | 04-Jun-2024 | ||
| JP-2026514449-A | Novel mettl3 inhibitors and their therapeutic use | Pending | 30-Mar-2023 | ||
| AU-2024244637-A1 | Novel mettl3 inhibitors and use thereof in therapy | Pending | 30-Mar-2023 | ||
| EP-4688768-A1 | Novel mettl3 inhibitors and use thereof in therapy | Pending | 30-Mar-2023 | ||
| WO-2024200835-A1 | Novel mettl3 inhibitors and use thereof in therapy | Inactive | 30-Mar-2023 | C07D401/14 |
AQEMIA Signals
AQEMIA Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cathay Capital | PE/Buyout | Minority | ||
| Cathay Innovation | Venture Capital | Minority | ||
| Idinvest Partners | PE/Buyout | Minority | ||
| Wendel Group | Family Office | Minority | ||
| La French Tech | Accelerator/Incubator |
AQEMIA FAQs
-
When was AQEMIA founded?
AQEMIA was founded in 2019.
-
Where is AQEMIA headquartered?
AQEMIA is headquartered in Paris, France.
-
What is the size of AQEMIA?
AQEMIA has 85 total employees.
-
What industry is AQEMIA in?
AQEMIA’s primary industry is Drug Discovery.
-
Is AQEMIA a private or public company?
AQEMIA is a Private company.
-
What is AQEMIA’s current revenue?
The current revenue for AQEMIA is .
-
How much funding has AQEMIA raised over time?
AQEMIA has raised $69.5M.
-
Who are AQEMIA’s investors?
Cathay Capital, Cathay Innovation, Idinvest Partners, Wendel Group, and La French Tech are 5 of 14 investors who have invested in AQEMIA.
-
Who are AQEMIA’s competitors?
insitro, Exscientia, AbCellera Biologics, Ariana Pharma, and Relay Therapeutics are some of the 9 competitors of AQEMIA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process